Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Chunquan Sheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9489-804X; OpenAlex author ID A5057853505, A5121063646. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
5
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 4

  1. Dual-targeting evodiamine analogue overcomes pancreatic cancer immunotherapy resistance by inducing immunogenic cell death. Co-author DOI 10.1016/j.bcp.2026.118059↗
  2. Discovery of Potent PDEδ/NAMPT Dual Inhibitors: Preclinical Evaluation in KRAS Mutant Pancreatic Cancer Cells. Co-author DOI 10.1021/acs.jmedchem.4c02636↗
  3. RMC-7977, a highly selective inhibitor of the active RAS-GTP to treat pancreatic cancer. Last author DOI 10.1016/j.apsb.2024.07.014↗
  4. Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer. Last author DOI 10.1002/anie.201915896↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shipeng He · 2 shared papers, 2020–2025 · strength 0.39
  2. Yingqi Song · 1 shared paper, 2024 · strength 0.36
  3. Yaojin Zhu · 1 shared paper, 2025 · strength 0.26
  4. Wei Wang · 1 shared paper, 2026 · strength 0.25
  5. Xiaomei Luo · 1 shared paper, 2026 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.